MRNA · 8-K · 20260731PR000147
Licensing / Collaboration Deals
Moderna, Inc. · 2026-07-31 · Importance 40 · Surprise 42 · In source text
Moderna signed a Brazil collaboration with a local manufacturer supporting a supply agreement for COVID vaccines. In the European Union, Moderna signed a joint procurement contract with the European Commission on behalf of six countries for up to 24 million doses of mRESVIA. The company identified higher collaboration and stand-ready manufacturing revenue as offsets to lower COVID vaccine sales in the second quarter. Moderna also continues advancing mRNA-4157 with Merck across nine Phase 2 and Phase 3 trials.
Key facts
- Moderna is advancing mRNA-4157 (intismeran autogene) in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, NSCLC, bladder cancer and renal cell carcinoma. source
- Moderna's Phase 3 study of intismeran includes monotherapy and combination with KEYTRUDA QLEX for high-risk Stage 1 NSCLC announced last quarter. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | — | Moderna is advancing mRNA-4157 (intismeran autogene) in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials… |